Vikram Purohit
Stock Analyst at Morgan Stanley
(0.81)
# 3,739
Out of 4,761 analysts
170
Total ratings
27.42%
Success rate
-13.51%
Average return
Main Sectors:
Stocks Rated by Vikram Purohit
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZBIO Zenas BioPharma | Maintains: Overweight | $40 → $35 | $7.83 | +347.00% | 2 | Dec 11, 2024 | |
| INCY Incyte | Maintains: Equal-Weight | $64 → $69 | $72.11 | -4.31% | 23 | Oct 30, 2024 | |
| FHTX Foghorn Therapeutics | Maintains: Equal-Weight | $6 → $9 | $5.23 | +72.08% | 9 | Sep 24, 2024 | |
| GMAB Genmab | Maintains: Equal-Weight | $31 | $22.34 | +38.76% | 2 | Sep 11, 2024 | |
| SLRN Acelyrin | Maintains: Equal-Weight | $13 → $6 | $2.60 | +130.77% | 7 | Aug 19, 2024 | |
| HALO Halozyme Therapeutics | Maintains: Overweight | $59 → $64 | $57.75 | +10.82% | 6 | Aug 7, 2024 | |
| ABSI Absci | Initiates: Overweight | $7 | $4.96 | +41.13% | 1 | Jul 3, 2024 | |
| ASND Ascendis Pharma | Maintains: Equal-Weight | $116 → $140 | $152.43 | -8.15% | 18 | May 16, 2024 | |
| AXSM Axsome Therapeutics | Upgrades: Overweight | $90 → $115 | $137.75 | -16.52% | 18 | Apr 29, 2024 | |
| ABVX ABIVAX Société Anonyme | Maintains: Equal-Weight | $15 → $16 | $8.08 | +98.02% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $4.21 | +612.59% | 1 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $22 | $7.31 | +200.96% | 6 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $10 | $13.02 | -23.20% | 8 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $46 → $6 | $1.61 | +272.67% | 1 | Nov 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $43 → $42 | $7.27 | +477.72% | 8 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $8 → $11 | $9.28 | +18.53% | 1 | Jul 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $23 | $1.78 | +1,164.04% | 4 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $38 → $41 | $36.81 | +11.38% | 12 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $120 → $40 | $22.12 | +80.83% | 7 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $13 | $1.50 | +766.67% | 1 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $39 → $38 | $22.64 | +67.84% | 6 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $24 → $20 | $13.17 | +51.86% | 5 | Aug 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $11 → $10 | $9.32 | +7.35% | 11 | Jul 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $18 → $7 | $13.17 | -46.85% | 8 | Dec 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $2.17 | +913.82% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $40 → $20 | $4.40 | +355.06% | 2 | Aug 5, 2020 |
Zenas BioPharma
Dec 11, 2024
Maintains: Overweight
Price Target: $40 → $35
Current: $7.83
Upside: +347.00%
Incyte
Oct 30, 2024
Maintains: Equal-Weight
Price Target: $64 → $69
Current: $72.11
Upside: -4.31%
Foghorn Therapeutics
Sep 24, 2024
Maintains: Equal-Weight
Price Target: $6 → $9
Current: $5.23
Upside: +72.08%
Genmab
Sep 11, 2024
Maintains: Equal-Weight
Price Target: $31
Current: $22.34
Upside: +38.76%
Acelyrin
Aug 19, 2024
Maintains: Equal-Weight
Price Target: $13 → $6
Current: $2.60
Upside: +130.77%
Halozyme Therapeutics
Aug 7, 2024
Maintains: Overweight
Price Target: $59 → $64
Current: $57.75
Upside: +10.82%
Absci
Jul 3, 2024
Initiates: Overweight
Price Target: $7
Current: $4.96
Upside: +41.13%
Ascendis Pharma
May 16, 2024
Maintains: Equal-Weight
Price Target: $116 → $140
Current: $152.43
Upside: -8.15%
Axsome Therapeutics
Apr 29, 2024
Upgrades: Overweight
Price Target: $90 → $115
Current: $137.75
Upside: -16.52%
ABIVAX Société Anonyme
Apr 11, 2024
Maintains: Equal-Weight
Price Target: $15 → $16
Current: $8.08
Upside: +98.02%
Apr 1, 2024
Initiates: Overweight
Price Target: $30
Current: $4.21
Upside: +612.59%
Feb 28, 2024
Maintains: Equal-Weight
Price Target: $20 → $22
Current: $7.31
Upside: +200.96%
Nov 13, 2023
Maintains: Overweight
Price Target: $45 → $10
Current: $13.02
Upside: -23.20%
Nov 7, 2023
Downgrades: Equal-Weight
Price Target: $46 → $6
Current: $1.61
Upside: +272.67%
Aug 29, 2023
Maintains: Overweight
Price Target: $43 → $42
Current: $7.27
Upside: +477.72%
Jul 13, 2023
Maintains: Equal-Weight
Price Target: $8 → $11
Current: $9.28
Upside: +18.53%
Jun 5, 2023
Maintains: Equal-Weight
Price Target: $20 → $23
Current: $1.78
Upside: +1,164.04%
Dec 19, 2022
Maintains: Equal-Weight
Price Target: $38 → $41
Current: $36.81
Upside: +11.38%
Dec 12, 2022
Maintains: Equal-Weight
Price Target: $120 → $40
Current: $22.12
Upside: +80.83%
Nov 10, 2022
Initiates: Equal-Weight
Price Target: $13
Current: $1.50
Upside: +766.67%
Nov 4, 2022
Maintains: Equal-Weight
Price Target: $39 → $38
Current: $22.64
Upside: +67.84%
Aug 24, 2022
Maintains: Equal-Weight
Price Target: $24 → $20
Current: $13.17
Upside: +51.86%
Jul 25, 2022
Maintains: Underweight
Price Target: $11 → $10
Current: $9.32
Upside: +7.35%
Dec 10, 2021
Downgrades: Underweight
Price Target: $18 → $7
Current: $13.17
Upside: -46.85%
Aug 10, 2021
Initiates: Overweight
Price Target: $22
Current: $2.17
Upside: +913.82%
Aug 5, 2020
Maintains: Equal-Weight
Price Target: $40 → $20
Current: $4.40
Upside: +355.06%